AcroMetrix BCR-ABL External Molecular Panel: An Accurate Testing Method for Chronic Myeloid Leukemia
To support the validation and verification of new assays and to challenge the existing assays in oncology testing, Thermo Fisher Scientific launches Thermo Scientific Acrometrix BCR-ABL Panel. The ...
Expression of CD74 by AML blasts and cell lines, and enhanced in vitro cytotoxicity of anti-CD74 antibody after interferon-gamma (IFN-γ) treatment. Background: Current NCCN guidelines recommend ...
BACKGROUND: BCR-ABL tyrosine kinase inhibitors (TKIs) have been increasingly linked to pulmonary arterial hypertension (PAH) since 2009, although supporting evidence is limited. Our objective was to ...
SUNNYVALE, Calif., Oct. 2, 2019 /PRNewswire/ -- Cepheid today announced that it has received clearance from the U.S. Food and Drug Administration for Xpert BCR-ABL Ultra for monitoring disease burden ...
ARIAD is advancing its investigational, pan-BCR-ABL inhibitor, ponatinib, in the pivotal PACE trial of patients with resistant or intolerant CML and Ph+ ALL, or those with the T315I mutation.
ARIAD Pharmaceuticals, Inc.Kendra Adams, 617-503-7028orLiza Heapes, 617-621-2315orKatherine Clock, 503-459-4974 and (NASDAQ: ARIA) today announced that MolecularMD has voluntarily withdrawn its ...
FREMONT, Calif., Oct. 17, 2019 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced the availability of the Thermo Scientific Acrometrix BCR-ABL Panel, its ...
FRANKLIN LAKES, N.J. and PORTLAND, Ore., June 2, 2011 /PRNewswire/ -- Medco Health Solutions, Inc. (NYSE: MHS) and MolecularMD Corp. today announce the launch of a personalized medicine program for ...
Asuragen will develop international scale calibrators and software reporting tools. Asuragen inked an exclusive agreement with Novartis to develop international scale (IS) calibrators and laboratory ...
The oncology landscape is rapidly evolving with new biomarker discoveries and potential targeted treatment options. Consequently, the medical community must work together to develop timely and ...
Patrick J. Muraca is president and chief executive cfficer, co-founder and board member of Pittsfield-based Nuclea Biotechnologies. PITTSFIELD — As Nuclea closed out a year of rapid growth, it signed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results